🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase III

Oncology programs at Phase III — ClinicalTrials.gov pipeline intelligence.

Programs
1,266

Quick answer

Oncology Phase III programs: NovaPharmaNews indexes 1,266 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 18 of 27

  1. Pembrolizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 3 mab active

    1 trial

  2. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Urinary Bladder Neoplasms

    phase 3 small molecule active

    1 trial

  3. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Metastatic Esophageal Squamous Cell Carcinoma

    phase 3 mab active

    1 trial

  4. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Triple Negative Breast Neoplasms

    phase 3 mab completed

    1 trial

  5. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Gastric Neoplasms

    phase 3 mab completed

    1 trial

  6. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Endometrial Neoplasms

    phase 3 mab active

    1 trial

  7. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 3 small molecule active

    1 trial

  8. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Renal Cell

    phase 3 mab active

    1 trial

  9. Pembrolizumab (K)

    Merck KGaA, Darmstadt, Germany

    Breast Cancer

    phase 3 mab active

    1 trial

  10. Pembrolizumab 25 MG/ML [Keytruda]

    United Therapeutics Europe Ltd

    Lung Cancer, Nonsmall Cell

    phase 3 small molecule active

    1 trial

  11. Pembrolizumab/Vibostolimab

    Merck KGaA, Darmstadt, Germany

    Lung Neoplasms

    phase 3 mab completed

    1 trial

  12. Pemetrexed

    Boehringer Ingelheim

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  13. Pemetrexed

    Eli Lilly and Company

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    2 trials

  14. Pemetrexed

    Regeneron UK Limited

    Carcinoma，Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  15. Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, TAGRISSO 40 mg film-coated tablets, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 100 mg powder for concentrate for solution for infusion, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  16. Pemigatinib

    Incyte

    Unresectable Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  17. Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide with a Non-Randomized, Single Arm US Extension of Mosunetuzumab in Combination with Lenalidomide in Patients with Follicular Lymphoma After at Least One Line of Systemic Therapy

    Hoffmann-La Roche

    Relapsed/refractory follicular lymphoma

    phase 3 other active

    1 trial

  18. Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Phesgo 600 mg/600 mg solution for injection, Herceptin 150 mg powder for concentrate for solution for infusion

    Hoffmann-La Roche

    HER2-POSITIVE EARLY BREAST CANCER

    phase 3 small molecule active

    1 trial

  19. Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Phesgo 600 mg/600 mg solution for injection

    Fondazione Telethon ETS

    Invasive Breast Cancer

    phase 3 small molecule active

    1 trial

  20. Phesgo 600 mg/600 mg solution for injection, Herceptin 600 mg solution for injection in vial, Perjeta 420 mg concentrate for solution for infusion, Phesgo 1200 mg/600 mg solution for injection, Kadcyla 160 mg powder for concentrate for solution for infusion.

    Hoffmann-La Roche

    Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  21. Placebo

    Amgen

    Breast Cancer

    phase 3 small molecule terminated

    1 trial

  22. Placebo

    Eli Lilly and Company

    Hepatocellular Carcinoma

    phase 3 mab completed

    1 trial

  23. Placebo

    Regeneron UK Limited

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  24. Placebo

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  25. Placebo

    Sanofi Pasteur

    Colorectal Neoplasms

    phase 3 small molecule completed

    1 trial

  26. Placebo

    HALOZYME THERAPEUTICS, INC.

    Pancreatic Ductal Carcinoma

    phase 3 small molecule terminated

    1 trial

  27. Placebo (Saline 0.9% (weight per volume; w/v)) for Pertuzumab, PERTUZUMAB, TRASTUZUMAB, PACLITAXEL, DS-8201a, DOCETAXEL

    AstraZeneca AB

    HER2-positive metastatic breast cancer

    phase 3 small molecule active

    1 trial

  28. Placebo - film-coated tablets, Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer

    phase 3 small molecule active

    1 trial

  29. Placebo JNJ-78278343, Placebo JNJ-78278343, JNJ-78278343, JNJ-78278343

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  30. Placebo for BMS-936558, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer

    phase 3 small molecule active

    1 trial

  31. Placebo for Capivasertib, PACLITAXEL, Capivasertib, Capivasertib

    AstraZeneca AB

    Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  32. Placebo for Opdivo, Rubraca 200 mg film-coated tablets, Rubraca 250 mg film-coated tablets, Rubraca 300 mg film-coated tablets, OPDIVO 10 mg/mL concentrate for solution for infusion., Placebo for Rubraca

    pharmaand GmbH

    Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer

    phase 3 small molecule active

    1 trial

  33. Placebo for pembrolizumab, ENZALUTAMIDE , PEMBROLIZUMAB

    Merck Sharp and Dohme

    Metastatic hormone sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  34. Placebo for pembrolizumab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , FLUOROURACIL , OXALIPLATIN , CISPLATIN

    Merck Sharp and Dohme

    Gastric and gastric esophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  35. Placebo is identical to the active drugs but without the active drug substance to maintain study blinding. Niraparib placebo tablets, Dostarlimab placebo infusion bags, JEMPERLI 500 mg concentrate for solution for infusion

    TESARO Bio Netherlands B.V.

    Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  36. Placebo matching REGN7508, REGN7508

    Lacuna Pharma Pty Ltd

    Cancer-Associated Thrombosis (CAT).

    phase 3 small molecule active

    1 trial

  37. Placebo tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Hoffmann-La Roche

    Small cell lung cancer (SCLC)

    phase 3 small molecule active

    1 trial

  38. Placebo to Keytruda - Normal Saline Solution, GEMCITABINE, CISPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Cis-eligible Muscle-invasive bladder cancer.

    phase 3 small molecule active

    1 trial

  39. Placebo to Pembrolizumab, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Locally Advanced Cervical Cancer

    phase 3 small molecule active

    1 trial

  40. Placebo to Ponsegromab (PF-06946860), CALCIUM LEVOFOLINATE PENTAHYDRATE, Ponsegromab (PF-06946860)

    Pfizer Australia Pty Ltd

    Cancer cachexia

    phase 3 small molecule active

    1 trial

  41. Placebo to capivasertib, Capivasertib, Bendadocel 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Capivasertib, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung

    AstraZeneca AB

    Metastatic Castration Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  42. Placebo to match LY, PEMBROLIZUMAB , DURVALUMAB

    Eli Lilly Co.

    Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  43. Placebo to match LY3537982, PEMBROLIZUMAB , PEMETREXED , CARBOPLATIN , CISPLATIN

    Eli Lilly Co.

    Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  44. Placebo to match abemaciclib, Verzenios 50 mg film-coated tablets, FULVESTRANT

    Eli Lilly Co.

    Breast Neoplasm, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  45. Placebo with a matching appearance to 100 mg niraparib capsules, filled with an excipient blend for clinical development., NIRAPARIB TOSILATE MONOHYDRATE

    TESARO Bio Netherlands B.V.

    Homologous recombination deficiency advanced ovarian cancer

    phase 3 small molecule active

    1 trial

  46. Placebo, CEMIPLIMAB

    Ningbo Cancer Hospital

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  47. Placebo, capsule, ZYTIGA 500 mg film-coated tablets, Prednison acis 5 mg, Tabletten, Fuzuloparib

    Lacuna Pharma Pty Ltd

    Metastatic Castration-Resistant Prostate Cancer

    phase 3 small molecule active

    1 trial

  48. Placebos

    Jian Li

    Advanced Non-small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many oncology Phase III programs exist?

1,266 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.